

---

**CORRIGENDUM****2017 FDA drug approvals***Asher Mullard**Nature Reviews Drug Discovery* **17**, 81–85 (2018)

Semaglutide is the sixth GLP1 agonist to receive FDA approval, not the fifth as originally noted. This correction has been made in the print and online versions.